Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

Exclusion Criteria

• •The patient has undergone any systemic anti-cancer treatment for NSCLC, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment, etc.;
• •The patient suffers from any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina pectoris, angina pectoris that starts to attack within the last 3 months, congestive heart failure \[≥ Grade II specified by New York Heart Association (NYHA)\], cardiac infarction (6 months before enrollment), severe arrhythmia and liver, kidney or metabolic diseases that requires drug treatment;
• •The patient is a carrier of HIV;
• •The patient has had or is currently suffering from interstitial lung disease;
• •The patient had undergone other major systemic operations or suffered from severe trauma within 3 months before the trial;
• •The patient is allergic to befotertinib or its any excipients;
• •The patient is allergic to bevacizumab or its any excipients;
• •The patient is allergic to platinum-based double chemotherapy or its any excipients;
• •The female patient is in pregnancy or lactation period;
• •There are any conditions under which the investigator considers the patient is not suitable to be enrolled.